Human TRAIL ELISA Kit

Contact us
Diaclone
Product Code: 850.770.048
Product Group: ELISA Kits
Supplier: Diaclone
CodeSizePrice
850.770.0481 x 48 Discovery (pre-coated)£227.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Regulatory Status: RUO
Application: Enzyme-Linked Immunosorbent Assay (ELISA)

Further Information

Antigen Synonyms:
Apo2L CD253
Assay Range:
93.75-3000 pg/ml
Cross reaction:
No cross reactivity with other human soluble molecules
Description:
Diaclone ELISA Kits include pre-coated strip plates biotinylated secondary antibody standards controls (where applicable) buffers streptavidin-HRP TMB stop reagents and a detailed procedure.
Detection Target:
TRAIL / Apo2L
Incubation:
3h45
Reactivity:
Human
Research Area:
Apoptosis
Sample Size:
100 µl
Sample Types:
Serum Plasma Cell culture supernatant
Sensitivity:
64 pg/ml
Specificity:
Recognizes both natural and recombinant soluble human Trail

References

  1. Herbeuval J. P. et al. AIDS. 2009 Jan 2; 23(1): 35?40. . HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and SIV-infected macaques. https://pubmed.ncbi.nlm.nih.gov/19050384/
  2. Mielczarek-Palacz M. et al. Cells. 2020 Mar; 9(3): 612. . Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand Inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer?Participation in Pathogenesis or a Possible Clinical Use?. https://pubmed.ncbi.nlm.nih.gov/32143328/
  3. Arik H. O. et al.Med Sci Monit.2013; 19: 712-5. Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers.. https://www.ncbi.nlm.nih.gov/pubmed/23986130
  4. Audige A. et al. J Immunol.2006; 177(9): 6227-37.. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. https://www.ncbi.nlm.nih.gov/pubmed/17056552
  5. Audo R. et al. Arthritis Res Ther.2015; 17: 193. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.. https://www.ncbi.nlm.nih.gov/pubmed/26220665
  6. Barblu L. and J. P. HerbeuvalPLoS One2012;7(3): e32874. Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4+ T cells and apoptosis.. https://www.ncbi.nlm.nih.gov/pubmed/22412938
  7. Bisgin A. et al.BMC Cancer2012;12:58. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.. https://www.ncbi.nlm.nih.gov/pubmed/22313795
  8. Bremer E. et al. Cancer Res. 2005; 65(8): 3380 - 3388. Target Cell-Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7. https://www.ncbi.nlm.nih.gov/pubmed/15833872
  9. Cassatella M. A. et al. J Leukoc Biol. 2006; 79(1): 123-32.. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. https://www.ncbi.nlm.nih.gov/pubmed/16244105
  10. Castellino G. et al. Lupus2007; 16(7): 479-482.. Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. https://www.ncbi.nlm.nih.gov/pubmed/17670845
  11. Celik B. et al.Med Sci Monit.2013;19: 875-82. Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.. https://www.ncbi.nlm.nih.gov/pubmed/24145180
  12. Chehimi J. et al.J. Virol.2010; 84(6): 2762-2773. Inability of Plasmacytoid Dendritic Cells To Directly Lyse HIV-Infected Autologous CD4+ T Cells despite Induction of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. https://www.ncbi.nlm.nih.gov/pubmed/20042498
  13. de Bruyn M et al. Clin. Cancer Res. 2011; 17: 5626 - 5637. Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells. https://www.ncbi.nlm.nih.gov/pubmed/21753155
  14. French M. A. et al.J Infect Dis.2009; 200(8):1212-5. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. https://www.ncbi.nlm.nih.gov/pubmed/19728788
  15. Gasper-Smith N. et al. J. Virol.2008; 82:7700-7710.. Induction of Plasma (TRAIL) TNFR-2 Fas Ligand and Plasma Microparticles After HIV-1 Transmission: Implications for HIV-1 Vaccine Design.. https://www.ncbi.nlm.nih.gov/pubmed/18508902